Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients
| Autor: | GABRIELA DROC, MIRCEA ISTRATE, ADRIANA MERCAN-STANCIU, MIHAI DODOT, TEODORA ISAC, LETITIA TOMA, ANCA ZGURA, ANCA TRIFAN, ANDREEA NICOLETA SERBANICA, LAURA ILIESCU, LAURENTIU MICU |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
Cancer Research Ritonavir Macrocyclic Compounds Genotype Proline Headache Valine Bilirubin Nausea Hepacivirus Hepatitis C Chronic Antiviral Agents Hepatitis C General Biochemistry Genetics and Molecular Biology Treatment Outcome Renal Dialysis Humans Drug Therapy Combination Anilides Carbamates Transaminases Fatigue Research Article |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| DOI: | 10.21873/invivo.13033 |
| Popis: | Background/Aim: The aim of this study was to determine the safety and efficacy of a direct-acting antiviral treatment, ombitasvir/paritaprevir/ritonavir and dasabuvir, without ribavirin, in a real-life setting. Patients and Methods: We performed a prospective observational study including 108 patients undergoing hemodialysis for end-stage kidney disease, referred to our clinic for antiviral therapy for chronic hepatitis C virus infection. Patients received treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, for 12 weeks. Sustained virologic response (SVR) was defined as undetectable viremia at 12 weeks after the end of therapy. For safety analysis, we monitored serum levels of hemoglobin, albumin, total bilirubin, alanine-aminotransferase and aspartate- aminotransferase at the beginning and end of therapy, as well as at SVR. Verbal Numeric Rating Scale was used to assess the presence of nausea, headaches and fatigue. Results: We noted a high prevalence of diabetic and hypertensive nephropathy as the underlying cause of chronic kidney disease. Most of the patients had F2 and F3 liver fibrosis (32.40% and 34.25%, respectively). The SVR rate was 96.2% (103/107 patients). We recorded an unrelated death after the completion of antiviral therapy. We found increased levels of nausea, headaches and fatigue at the end of therapy compared to at initiation, The presence and degree of symptoms did not correlate with the underlying cause of renal disease (p=0.72) nor with the degree of fibrosis (p=0.08). Minimal increases in transaminases and bilirubin were recorded at the end of treatment, with no statistical significance. Conclusion: Oral antiviral therapy with ombitasvir/paritaprevir/ritonavir and dasabuvir can be safely used in hemodialysis patients, with similar response rates compared to the general population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|